Patients (215) were evaluated with metrizamide, a new water-soluble contrast agent for use in the subarachnoid spaces. Side effects were reported in 67%; 39% were moderate or severe. Cervical injections monitored by fluoroscopy provided the most precise positioning of the medium. The benefits of metrizamide use outweigh its risks.